One- & two-year survival rates of 94% and 88% announced from Phase 1b trial of investigational PD-1 checkpoint inhibitor nivolumab and yervoy® (ipilimumab) in advanced melanoma
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...